FY2026 Earnings Estimate for BMY Issued By Leerink Partnrs

Bristol Myers Squibb Company (NYSE:BMY) – Leerink Partnrs raised their FY2026 earnings estimates for shares of Bristol Myers Squibb in a research report issued to clients and investors on Sunday, November 23rd. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will earn $5.97 per share for the year, up from their prior estimate of $5.89. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Leerink Partnrs also issued estimates for Bristol Myers Squibb’s FY2027 earnings at $6.10 EPS and FY2029 earnings at $5.37 EPS.

BMY has been the subject of several other reports. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Dbs Bank upgraded Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Scotiabank initiated coverage on Bristol Myers Squibb in a report on Thursday, November 13th. They set a “sector perform” rating and a $45.00 price target on the stock. Cantor Fitzgerald reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Four equities research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $54.42.

Bristol Myers Squibb Price Performance

BMY stock opened at $49.05 on Tuesday. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The firm has a market cap of $99.84 billion, a price-to-earnings ratio of 19.78, a PEG ratio of 2.23 and a beta of 0.33. The company’s fifty day simple moving average is $45.37 and its 200 day simple moving average is $46.58. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. During the same period in the prior year, the firm posted $1.80 EPS. The company’s quarterly revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd were given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.1%. The ex-dividend date of this dividend was Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio is presently 83.78%.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president directly owned 167,379 shares in the company, valued at $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.09% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Bristol Myers Squibb by 0.5% during the third quarter. Vanguard Group Inc. now owns 195,984,009 shares of the biopharmaceutical company’s stock worth $8,838,879,000 after acquiring an additional 1,058,803 shares in the last quarter. State Street Corp boosted its stake in Bristol Myers Squibb by 2.0% during the 3rd quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company’s stock valued at $4,356,445,000 after purchasing an additional 1,855,238 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Bristol Myers Squibb by 16.8% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock worth $3,277,456,000 after purchasing an additional 10,195,775 shares in the last quarter. Geode Capital Management LLC increased its holdings in Bristol Myers Squibb by 1.6% during the 2nd quarter. Geode Capital Management LLC now owns 46,176,690 shares of the biopharmaceutical company’s stock worth $2,132,976,000 after purchasing an additional 723,459 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Bristol Myers Squibb in the second quarter worth approximately $1,554,154,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.